These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17996591)

  • 1. Prognostic factors and staging in multiple myeloma.
    Fonseca R; San Miguel J
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1115-40, ix. PubMed ID: 17996591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic features of multiple myeloma.
    San Miguel JF; García-Sanz R
    Best Pract Res Clin Haematol; 2005; 18(4):569-83. PubMed ID: 16026738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
    Haferlach T; Löffler H
    Leukemia; 1997 Dec; 11 Suppl 5():S5-9. PubMed ID: 9436931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: prognostic factors and treatment modalities.
    Michiels JJ
    Neth J Med; 1992 Jun; 40(5-6):254-70. PubMed ID: 1436263
    [No Abstract]   [Full Text] [Related]  

  • 6. Autologous stem-cell transplantation for multiple myeloma.
    Louw VJ; Louw H; Webb MJ
    N Engl J Med; 2009 Sep; 361(11):1118-9; author reply 1119. PubMed ID: 19741236
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple myeloma. Role of prognostic factors and staging in a therapeutic program].
    Bolis S; Bregani ER; Rossini F; Casaroli I; Lanzi E; Maffè P; Baldicchi L; Borin L; Mingozzi S; Tripputi P
    Recenti Prog Med; 1994 Jan; 85(1):49-55. PubMed ID: 8184181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
    Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
    Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
    Stewart AK; Fonseca R
    J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
    Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
    Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC; Maltezas D; Tzenou T; Koulieris E; Bradwell AR
    Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network.
    Oncology (Williston Park); 1998 Nov; 12(11A):317-51. PubMed ID: 10028515
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple myeloma: treatment options for an incurable disease.
    Pandit SR
    J Assoc Physicians India; 2005 Dec; 53():1060-4. PubMed ID: 16572964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.